Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.

Arango NP, Brusco L, Shaw KRM, Chen K, Eterovic AK, Holla V, Johnson A, Litzenburger B, Khotskaya YB, Sanchez N, Bailey A, Zheng X, Horombe C, Kopetz S, Farhangfar CJ, Routbort M, Broaddus R, Bernstam EV, Mendelsohn J, Mills GB, Meric-Bernstam F.

Oncotarget. 2019 Aug 27;10(50):5254. doi: 10.18632/oncotarget.27176. eCollection 2019 Aug 27.

2.

A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.

Arango NP, Brusco L, Mills Shaw KR, Chen K, Eterovic AK, Holla V, Johnson A, Litzenburger B, Khotskaya YB, Sanchez N, Bailey A, Zheng X, Horombe C, Kopetz S, Farhangfar CJ, Routbort M, Broaddus R, Bernstam EV, Mendelsohn J, Mills GB, Meric-Bernstam F.

Oncotarget. 2017 Jun 27;8(26):41806-41814. doi: 10.18632/oncotarget.16018. Erratum in: Oncotarget. 2019 Aug 27;10(50):5254.

3.

Clinical actionability enhanced through deep targeted sequencing of solid tumors.

Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK.

Clin Chem. 2015 Mar;61(3):544-53. doi: 10.1373/clinchem.2014.231100. Epub 2015 Jan 27.

4.

The impact of tumor heterogeneity on patient treatment decisions.

Farhangfar CJ, Meric-Bernstam F, Mendelsohn J, Mills GB, Lucio-Eterovic AK.

Clin Chem. 2013 Jan;59(1):38-40. doi: 10.1373/clinchem.2012.194712. Epub 2012 Nov 9. No abstract available.

5.

The BATTLE to personalize lung cancer prevention through reverse migration.

Gold KA, Kim ES, Lee JJ, Wistuba II, Farhangfar CJ, Hong WK.

Cancer Prev Res (Phila). 2011 Jul;4(7):962-72. doi: 10.1158/1940-6207.CAPR-11-0232.

6.

Sensitive angiogenesis imaging of orthotopic bladder tumors in mice using a selective magnetic resonance imaging contrast agent containing VEGF121/rGel.

Cho EJ, Yang J, Mohamedali KA, Lim EK, Kim EJ, Farhangfar CJ, Suh JS, Haam S, Rosenblum MG, Huh YM.

Invest Radiol. 2011 Jul;46(7):441-9. doi: 10.1097/RLI.0b013e3182174fad.

PMID:
21512397

Supplemental Content

Loading ...
Support Center